Search results for "relap"

showing 10 items of 217 documents

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: …

2020

The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of hepatocellular carcinoma (HCC) was published in 2018, and covered the diagnosis, management, treatment and follow-up of early, intermediate and advanced disease. At the ESMO Asia Meeting in November 2018 it was decided by both the ESMO and the Taiwan Oncology Society (TOS) to convene a special guidelines meeting immediately after the Taiwan Joint Cancer Conference (TJCC) in May 2019 in Taipei. The aim was to adapt the ESMO 2018 guidelines to take into account both the ethnic and the geographic differences in practice associated with the treat…

0301 basic medicinemedicine.medical_specialtyESMO guidelinesDrug availability03 medical and health sciences0302 clinical medicineAdvanced diseaseAsian countryconsensuMedicineHCCReimbursementESMO guidelinePan-Asianbusiness.industryCancer conferenceRelapsed Hepatocellular CarcinomaHematologyhepatocellular carcinomaClinical Practice030104 developmental biologyOncologyconsensus030220 oncology & carcinogenesisFamily medicinebusiness
researchProduct

The impact of rituximab infusion protocol on the long-term outcome in anti-MuSK myasthenia gravis

2018

ObjectiveTo evaluate whether the clinical benefit and relapse rates in anti-muscle-specific kinase (MuSK) myasthenia gravis (MG) differ depending on the protocol of rituximab followed. MethodsThis retrospective multicentre study in patients with MuSK MG compared three rituximab protocols in terms of clinical status, relapse, changes in treatment, and adverse side effects. The primary effectiveness endpoint was clinical relapse requiring a further infusion of rituximab. Survival curves were estimated using Kaplan-Meier methods and survival analyses were undertaken using Cox proportional-hazards models. ResultsTwenty-five patients were included: 11 treated with protocol 4 + 2 (375 mg/m(2)/4 w…

0301 basic medicinemedicine.medical_specialtyTime to relapseRelapse rateGastroenterologyAssaigs clínics de medicaments03 medical and health sciencesMalalties del sistema nerviós0302 clinical medicineimmune system diseasesInternal medicineMedicineIn patientRelapse riskAdverse effectSurvival analysisbusiness.industryGeneral NeuroscienceNervous system DiseasesDrug testingmedicine.diseaseMyasthenia gravis030104 developmental biologyRituximabNeurology (clinical)business030217 neurology & neurosurgerymedicine.drug
researchProduct

User-Oriented Interface for Monitoring Affective Diseases in Patients with Bipolar Disorder Using Mobile Devices

2020

Nowadays the design of interfaces on mobile devices in the field of mental health is being studied to be applied in the functional criteria related to usability and user experience (UX). This article presents a methodological and conceptual development of an innovative telematics application oriented to control and management relapse prevention in bipolar disorder patients created by the Psychiatry and Clinical Psychology Unit of La Fe Hospital and the Polytechnic University of Valencia. Application called e-therapy aims to control affective diseases in bipolar disorder through the use of computer-assisted tests related to depression and mania among others. Its development and design took i…

050103 clinical psychologybusiness.industry05 social sciencesApplied psychologyUsabilitymedicine.diseaseRelapse preventionMental health030227 psychiatry03 medical and health sciences0302 clinical medicineMoodUser experience designmedicine0501 psychology and cognitive sciencesBipolar disordermedicine.symptomPsychologybusinessmHealthMania
researchProduct

Central nervous system involvement at first relapse in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycl…

2009

Background The prevalence of and risk factors for central nervous system recurrence in patients with acute promyelocytic leukemia are not well established and remain a controversial matter. Design and Methods Between 1996 and 2005, 739 patients with newly diagnosed acute promyelocytic leukemia enrolled in two consecutive trials (PETHEMA LPA96 and LPA99) received induction therapy-with all-trans retinoic acid and idarubicin. Consolidation therapy comprised three courses of anthracycline monochemotherapy (LPA96), with all-trans retinoic acid and reinforced doses of idarubicin in patients with an intermediate or high risk of relapse (LPA99). Central nervous system prophylaxis was not given. Re…

:Chemicals and Drugs::Organic Chemicals::Hydrocarbons::Hydrocarbons Cyclic::Hydrocarbons Aromatic::Polycyclic Hydrocarbons Aromatic::Naphthacenes::Anthracyclines::Daunorubicin::Idarubicin [Medical Subject Headings]:Diseases::Pathological Conditions Signs and Symptoms::Pathologic Processes::Disease Attributes::Recurrence [Medical Subject Headings]Male:Named Groups::Persons::Age Groups::Adult::Middle Aged [Medical Subject Headings]idarubicinGastroenterology:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Probability::Risk::Risk Factors [Medical Subject Headings]:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]Central Nervous System NeoplasmsLeukemia Promyelocytic AcuteRecurrenceRisk FactorsCumulative incidenceAntibiotics AntineoplasticHematologyMiddle Agedall-trans retinoic acidLeukemiamedicine.anatomical_structure:Named Groups::Persons::Age Groups::Adolescent [Medical Subject Headings]Femalemedicine.drugAcute promyelocytic leukemiaAdultcentral nervous system relapsemedicine.medical_specialty:Diseases::Neoplasms::Neoplasms by Histologic Type::Leukemia::Leukemia Myeloid::Leukemia Myeloid Acute [Medical Subject Headings]AnthracyclineAdolescentCentral nervous system:Check Tags::Male [Medical Subject Headings]TretinoinNeoplasias del sistema nervioso centralCentral nervous system diseaseTretinoinInternal medicine:Named Groups::Persons::Age Groups::Adult [Medical Subject Headings]medicineIdarubicinHumans:Named Groups::Persons::Age Groups::Adult::Aged [Medical Subject Headings]Letters to the Editor:Chemicals and Drugs::Organic Chemicals::Hydrocarbons::Hydrocarbons Acyclic::Alkenes::Polyenes::Carotenoids::Retinoids [Medical Subject Headings]Leucemia promielocítica agudaAgedAntibióticos antineoplásicosbusiness.industryprognostic factors:Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents::Antibiotics Antineoplastic [Medical Subject Headings]acute promyelocytic leukemiamedicine.diseaseSurgery:Diseases::Neoplasms::Neoplasms by Site::Nervous System Neoplasms::Central Nervous System Neoplasms [Medical Subject Headings]:Check Tags::Female [Medical Subject Headings]businessIdarubicin
researchProduct

ANALISI DI SICUREZZA DI SISTEMI DELL’IMPIANTO SPES

2014

Il progetto SPES prevede il bombardamento di un bersaglio in carburo di uranio con un fascio di protoni, in modo da generare, tramite reazione nucleare, specie radioattive all’interno del target. Le particelle radioattive generate vengono successivamente estratte, ionizzate, separate in massa ed accelerate come fascio di ioni radioattivo. Il presente lavoro di tesi ha riguardato lo studio di sicurezza di alcune unità dell'impianto SPES e si inserisce nell'ambito di una collaborazione di ricerca tra i Laboratori Nazionali di Legnaro ed il Dipartimento dell'Energia, sezione Nucleare, dell'Università degli Studi di Palermo. Tale attività ha comportato l'analisi sui componenti del sistema di pr…

ANALISI SICUREZZA RELAP5 EXCYTINFNSPESSettore ING-IND/19 - Impianti NucleariFMECA
researchProduct

Prognostic Factors in APL

2018

The prognosis of acute promyelocytic leukemia (APL) has significantly improved since the introduction of anthracyclines, but especially after the advent of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). The identification of prognostic factors is a key process in clinical investigation, since their recognition allows the stratification of disease risks and promotes refined therapeutic adjustments. In fact, most treatments are now designed following risk-adapted strategies in order to optimize the therapeutic efficacy and minimizing side effects. The efficacy of treatment is one major determinant in prognosis. Therefore, the impact of a number of disease and patient characteristi…

Acute promyelocytic leukemiaOncologymedicine.medical_specialtyChemotherapybusiness.industrymedicine.medical_treatmentDiseasemedicine.diseasePredictive valueClinical trialchemistry.chemical_compoundchemistryClinical investigationInternal medicinemedicineRelapse riskArsenic trioxidebusiness
researchProduct

Quantification of the risk of relapses after thyroid loboisthmusectomy for benign thyroid nodules

2006

AIM OF THE STUDY: To evaluate correlations between pre-operating epidemiological, clinical and diagnostic data and relapses concerning to patients operated on for benign thyroid nodules. MATERIAL AND METHODS: The AA. carried out a new ultrasonographic exam in 155 patients selected at random among 1012 treated by thyroid lobectomy between September 1976 and December 2002; 107 relapses were found (69%). The obtained data are analysed by chi2 test and a significant correlation between recurrence and data preceding first operation was found: non-homogeneous thyroid structure, multiple nodules, presence of peri-lesional halo, anti-thyroid antibodies, and non-adenomatous histological structure. C…

AdenomaAdultMaleChi-Square DistributionTime FactorsGoiterAge FactorsMiddle AgedGoitre relapse Thyroid lobectomyGraves DiseaseSex FactorsRecurrenceRisk FactorsThyroidectomyHumansFemaleThyroid NeoplasmsThyroid NoduleAgedFollow-Up StudiesGoiter NodularUltrasonography
researchProduct

Assisting relapse prevention in OCD using a novel mobile app-based intervention: A case report.

2018

Mobile health apps increase the accessibility of cognitive-behavioral–based interventions before, during, or following treatment. GGOC is a mobile app designed to challenge maladaptive beliefs in obsessive-compulsive disorder (OCD). This single-case study assesses the usefulness of GGOC as a relapse prevention tool for OCD. The patient was a 26-year-old woman with severe contamination and washing/cleaning OCD symptoms (Y-BOCS = 33). GGOC was used for relapse prevention following CBT treatment. The patient completed 47 levels dedicated to OCD-relevant maladaptive beliefs. Before and after GGOC, the Y-BOCS, Obsessive-Compulsive Inventory (OCI-R), Obsessive Beliefs Questionnaire (OBQ-20), and…

Adult050103 clinical psychologyObsessive-Compulsive Disordermedicine.medical_treatmentPsychological interventionRelapse preventionbehavioral disciplines and activities03 medical and health sciences0302 clinical medicineIntervention (counseling)mental disordersSecondary PreventionMedicineHumans0501 psychology and cognitive sciencesDepression (differential diagnoses)Cognitive Behavioral Therapybusiness.industry05 social sciencesMobile appsMobile Applicationshumanities030227 psychiatryCognitive behavioral therapyPsychiatry and Mental healthClinical PsychologyAnxietyFemalePshychiatric Mental Healthmedicine.symptombusinessClinical psychologyBulletin of the Menninger Clinic
researchProduct

Cognitive dysfunction in patients with relapsing-remitting multiple sclerosis

2006

Cognitive dysfunction is considered one of the clinical markers of multiple sclerosis (MS). However, in the literature there are inconsistent reports on the prevalence of cognitive dysfunction, and separate data for the relapsing-remitting (RR) type of the disease are not always presented. In this study, we submitted 461 RRMS patients to a battery of neuropsychological tests to investigate their impairment in various cognitive domains. As a consequence of the exclusion criteria, the sample is not fully representative of the entire population of RRMS patients. In this selected sample, when only the eight scores of a core battery (Mental Deterioration Battery) were considered (with respectiv…

Adult050103 clinical psychologymedicine.medical_specialtyMultiple Sclerosismultiple sclerosis cognition single digit modality test information processingNeuropsychological TestsAudiologyDevelopmental psychology03 medical and health sciencesCognitionMultiple Sclerosis Relapsing-Remitting0302 clinical medicineMemoryOutpatientsOutpatients; Humans; Patient Selection; Multiple Sclerosis Relapsing-Remitting; Cognition; Cognition Disorders; Italy; Demography; Memory; Adult; Language; Neuropsychological Tests; SpeechmedicineHumansSpeech0501 psychology and cognitive sciencesMemory disorderCognitive deficitDemographyLanguagemedicine.diagnostic_testPatient SelectionMemoriaMultiple sclerosiscognition impairment05 social sciencesCognitive disorderNeuropsychologyCognitionNeuropsychological testmedicine.diseaserelapsing-remittingItalyinformation processing speedNeurologymultiple sclerosiSettore MED/26 - NeurologiaNeurology (clinical)medicine.symptomCognition DisordersPsychology030217 neurology & neurosurgeryrelapsing remitting
researchProduct

Dimethyl fumarate treatment restrains the antioxidative capacity of T cells to control autoimmunity

2021

Abstract Dimethyl fumarate, an approved treatment for relapsing-remitting multiple sclerosis, exerts pleiotropic effects on immune cells as well as CNS resident cells. Here, we show that dimethyl fumarate exerts a profound alteration of the metabolic profile of human CD4+ as well as CD8+ T cells and restricts their antioxidative capacities by decreasing intracellular levels of the reactive oxygen species scavenger glutathione. This causes an increase in mitochondrial reactive oxygen species levels accompanied by an enhanced mitochondrial stress response, ultimately leading to impaired mitochondrial function. Enhanced mitochondrial reactive oxygen species levels not only result in enhanced T…

AdultCD4-Positive T-LymphocytesMaleDimethyl FumarateT cellAutoimmunityCD8-Positive T-Lymphocytesmedicine.disease_causeAntioxidantsCohort StudiesMiceYoung Adultchemistry.chemical_compoundMultiple Sclerosis Relapsing-RemittingImmune systemmedicineAnimalsHumanschemistry.chemical_classificationReactive oxygen speciesDimethyl fumarateExperimental autoimmune encephalomyelitisGlutathioneMiddle Agedmedicine.diseaseCell biologyMice Inbred C57BLmedicine.anatomical_structurechemistryFemaleNeurology (clinical)Immunosuppressive AgentsOxidative stressCD8Brain
researchProduct